Clinical outcome of parapneumonic empyema in children treated according to a standardized medical treatment

被引:0
作者
Marijke Proesmans
Brenda Gijsens
Patricia Van de Wijdeven
Herbert De Caluwe
Jan Verhaegen
Katrien Lagrou
Ellen Van Even
Francois Vermeulen
Kris De Boeck
机构
[1] University Hospital of Leuven,Department of Pediatrics, Pediatric Pulmonology
[2] University of Leuven,Department of Thoracic Surgery
[3] University of Leuven,Department of Microbiology
来源
European Journal of Pediatrics | 2014年 / 173卷
关键词
Empyema; Children; Treatment; Etiology;
D O I
暂无
中图分类号
学科分类号
摘要
Treatment of parapneumonic empyema (PE) consists of intravenous antibiotics and, in case of large effusions and persisting fever, pleural chest drain (±intrapleural fibrinolytics) or video-assisted surgical intervention. We standardized the treatment for PE in our tertiary care center choosing a first-step nonsurgical approach. The aim was to evaluate the need for surgery and to collect data on disease course, outcome, and microbiology. For all children treated for PE between 2006 and 2013, data were prospectively collected concerning treatment, length of stay, duration of fever, complications, and causative agent. Of 132 children treated for PE, 20 % needed surgical intervention. Analyzed per year, the need for surgery decreased from almost 40 % in 2007 to 0 % in 2010 again increasing to 40 % although this did not reach statistical significance (p = 0.115). Median duration of “in-hospital fever” was 5 days (IQR, 3–8). The duration of fever correlated with pleural LDH (r = 0.324; p = 0.002) and pleural glucose (r = −0.248; p = 0.021) and was inversely correlated with pleural pH (r = −0.249; p = 0.046). Based on pleural PCR data, 85 % of PE were caused by Streptococcus pneumoniae (40 % serotype 1). Conclusion: After introduction of a standardized primary medical approach (chest drain ± fibrinolysis) for PE in our institution, the need for surgical rescue interventions overall remained at 20 %, which is higher than in some other reports. Difference in microbiology or disease severity could not be proven.
引用
收藏
页码:1339 / 1345
页数:6
相关论文
共 174 条
[1]  
Andrade AL(2011)Pneumococcal disease manifestation in children before and after vaccination: what's new? Vaccine 29 C2-C14
[2]  
Toscano CM(2005)BTS guidelines for the management of pleural infection in children Thorax 60 i1-i21
[3]  
Minamisava R(2003)Incidence and etiologies of complicated parapneumonic effusions in children, 1996 to 2001 Pediatr Infect Dis J 22 499-504
[4]  
Costa PS(2006)Impact of the pneumococcal conjugate vaccine on pneumococcal parapneumonic empyema Pediatr Infect Dis J 25 250-254
[5]  
Andrade JG(2002)An epidemiological investigation of a sustained high rate of pediatric parapneumonic empyema: risk factors and microbiological associations Clin Infect Dis 34 434-440
[6]  
Balfour-Lynn IM(2012)The long-term outcomes of pediatric pleural empyema: a prospective study Arch Pediatr Adolesc Med 166 999-1004
[7]  
Abrahamson E(2000)Medical and surgical treatment of parapneumonic effusions: an evidence-based guideline Chest 118 1158-1171
[8]  
Cohen G(2003)BTS guidelines for the management of pleural infection Thorax 58 ii18-ii28
[9]  
Hartley J(2013)Experience with an evidence-based protocol using fibrinolysis as first line treatment for empyema in children J Pediatr Surg 48 1312-1315
[10]  
King S(2011)Emergence of parapneumonic empyema in the USA Thorax 66 663-668